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Summary
Introduction: What is the current status of photodynamic therapy (PDT) with regard to treating
malignant brain tumors? Despite several decades of effort, PDT has yet to achieve standard of
care.
Purpose: The questions we wish to answer are: where are we clinically with PDT, why is it not
standard of care, and what is being done in clinical trials to get us there.
Method: Rather than a meta-analysis or comprehensive review, our review focuses on who the
major research groups are, what their approaches to the problem are, and how their results
compare to standard of care. Secondary questions include what the effective depth of light
penetration is, and how deep can we expect to kill tumor cells.
Current results: A measurable degree of necrosis is seen to a depth of about 5mm. Cavitary PDT
with hematoporphyrin derivative (HpD) results are encouraging, but need an adequate Phase
III trial. Talaporﬁn with cavitary light application appears promising, although only a small case
series has been reported. Foscan for ﬂuorescence guided resection (FGR) plus intraoperative
cavitary PDT results were improved over controls, but are poor compared to other groups. 5-
Aminolevulinic acid-FGR plus postop cavitary HpD PDT show improvement over controls, but
the comparison to standard of care is still poor.
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53226,United States. Tel.: +1 114142667544; fax: +1 114142663466.
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1572-1000/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusion: Continued research in PDT will determine whether the advances shown will mit-
igate morbidity and mortality, but certainly the potential for this modality to revolutionize
the treatment of brain tumors remains. The various uses for PDT in clinical practice should
be pursued.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Photodynamic therapy (PDT) and related techniques —
where do we stand? Despite ﬁrst being used over 35 years
ago as an adjunctive measure in the treatment of cancer and
its subsequent study in multiple clinical trials internation-
ally, PDT and the related techniques of ﬂuorescence guided
resection (FGR) and photodiagnosis (PD) have yet to progress
as a standard of care [1]. In general, PDT does not describe
a single technique, rather a family of related protocols
involving a photosensitizer (PS), that when excited by light
irradiation, triggers an oxidative reaction. This in turn stimu-
lates production of reactive oxygen species from molecular
oxygen located within a cellular microenvironment (Fig. 1).
Photosensitizers have been shown to preferentially accumu-
late within tumor cells, allowing for targeted, PDT-induced
cytotoxicity of malignant cancer cells. Therefore, PDT may
be a viable treatment option in treatment of brain tumors
[2].
The interest in PDT as a treatment for high-grade
gliomas stems from both the nature of tumor growth and
limited effectiveness of modern therapies available to this
patient population [3]. While surgical resection (SR) and
fractionated radiation plus chemotherapy are mainstays of
treatment for most of these tumors, invasive growth pat-
terns, especially into eloquent regions of cerebrum [4], pose
an obstacle to gross total resection. In addition, as gross
total resection involves only the enhancing portion of the
tumor as seen on MRI scans, we must realize that it is not
likely that all occurrences of malignant material have been
removed. Tumors recur possibly because of residual tumor
left behind, either grossly viz. areas of function, or less
obviously in areas not associated with function. Work here
and other places suggest that there is a lot of potential for
tumor activity in the unenhancing areas of diffusion abnor-
mality. Possible concepts include residual distant tumor,
migration, or transformation. Unlike surgery and radiation,
PDT can treat areas of microinvasion and simultaneously
spare sensitive brain regions. This advantage over current
therapy may improve outcome in a patient population whose
survival and incidence of iatrogenic injury is overall quite
poor. There are many questions about PDT, however, which
remain to be answered prior to investigating its utility as a
standard adjuvant therapy.
First, the reported effects of PDT in clinical trials are con-
founded by an absence of standard treatment guidelines.
The variables that exist across studies include: dose, irra-
diation light wavelength, method of light delivery, choice
of PS, sensitivity of different tumor types, effectiveness
on recurrent tumor, and adjuvant use with chemotherapy
and radiation. Second, the analyses of PDT’s observed clin-
ical effects in these trials have mostly been conducted in
a retrospective fashion. Together, this has narrowed our
understanding of PDT in clinical practice.
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Figure 1 Simpliﬁed PDT scheme depicting photoexcitation of a photosensitizer from its ground state (PS) to a singlet excited
state (1PS), followed by intersystem crossing (ISC) to a long-lived triplet excited state (3PS). The latter can then interact with
ground state oxygen (3O2) or some electron/hydrogen donor to give reactive oxygen species (ROS) such as singlet molecular oxygen
(1O2) or free radicals such as superoxide and hydroxyl radical. If ROS conversion to non-reactive species (NRS) by antioxidants
or scavengers is inadequate, cell damage can occur, resulting in either death signaling for apoptosis, autophagy, or necrosis, or
pro-survival signaling. In tumors, the latter often reﬂects upregulation of nuclear factor-kappa B (NF-kB), cyclooxygenase 2 (COX2),
or inducible nitric oxide synthase (iNOS) and nitric oxide (NO). These and other pro-survival signals may result in faster growth in
cells that can cope with PDT stress.
Given the challenges of treating high-grade gliomas, it is
worthwhile to explore what has taken place in the ﬁeld of
PDT. In the long-term, it will be important to evaluate the
role of adjuvant PDT therapy in treating malignant, intracra-
nial tumors and also plan future steps needed to introduce
PDT as a viable component of multimodal strategies.
Background
Annually, approximately 44,000 new primary brain tumors
are diagnosed in the United States [5]. Malignant gliomas,
which include anaplastic astrocytomas (AA, WHO Grade III),
anaplastic oligodendrogliomas (AO, WHO Grade III), anaplas-
tic oligoastrocytoma (AOA, WHO Grade III) and Glioblastoma
(GBM, WHO Grade IV), are the second leading cause of can-
cer mortality in people under the age of 35 and the fourth
leading cause in those under the age of 54, and account for
approximately 13,000 deaths per year [5]. Themost common
malignant primary brain tumors in adults are GBMs, which
are highly lethal [6,7]. GBMs account for 52% of all parenchy-
mal brain tumor cases and 20% of all intracranial tumors
[8,9]. These highly aggressive tumors are derived from the
malignant transformation of either mature glial cells or neu-
ral stem cells [10,11]. In spite of recent advances in surgical
techniques, adjuvant radiation therapy, chemotherapies,
and other novel treatments targeting pathophysiological
characteristics like neovascularization in GBM, the prognosis
remains dismal. Local recurrence is the most common form
of relapse affecting upwards of 80% of cases [12,13]. Though
steps to optimize local control strategies are being coupled
to invasive interventions such as gross total resection and
adjuvant local irradiation, the current standard of care is
associated with a median survival time of 14.6 months [14].
Simply, surgeons encounter difﬁculty in achieving com-
plete resection of GBMs and other intracranial tumors
because these cancer cells often arise proximal to and
invade eloquent brain, which when injured can result in
debilitating neurological impairment. From a pharmacologi-
cal perspective, the blood—brain barrier (BBB) that protects
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the brain from foreign bodies such as bacteria also prevents
many systemically delivered chemotherapeutic agents from
ever reaching the target site of tumor. While novel drugs
and combination therapies continue to be investigated, it
appears that new therapies should aim to reconcile effec-
tiveness with precision, so as to achieve localized tumor
control that is especially necessary in cases of recurrence. In
this regard, photodynamic therapy is a viable option to con-
sider, as it aims at treating inﬁltrative tumor cells beyond
the resection cavity while sparing normal functioning brain.
PDT is considered a paradigm shift from the treatment
of tumors traditionally resected and targeted with systemic
chemotherapy. The principle behind PDT is that cancer cell
destruction is caused by light-induced activation of a pho-
tosensitizer that selectively accumulates within neoplastic
tissue. In a study by Whelan et al. [15], the mechanism
of selective localization of Photofrin was identiﬁed through
radiolabeling of photosensitizer with Indium-111 (111In). It
was reported that initial accumulation of the 111In-labeled
Photofrin in the area of the brain tumor was due to pas-
sive diffusion through the BBB, which had been disrupted
secondary to tumor growth. Interestingly, the concentra-
tion of the radiolabeled Photofrin in the tumor was found to
be much higher than what was accountable by BBB break-
down alone [15]. While the exact mechanism of the selective
uptake was not known, these ﬁndings demonstrated that
Photofrin had selectivity for tumor cells. Owing to this for-
tuitous discovery, the production of singlet oxygen (1O2) and
other reactive oxygen species (ROS) generated by PDT result
in targeted cytotoxicity of tumor cells (Fig. 1) [16—20]. In
summary, photosensitizer uptake and photoactivation are
critical for PDT efﬁcacy.
Technical considerations for PDT
Photosensitizers
Many different photosensitizers have been proposed and
studied for treating brain tumors. The ideal compound would
be non-toxic systemically, highly concentrated in malignant
tissue, activated at light wavelengths needed to achieve
deep brain tissue penetration, as well as minimal injury to
surrounding normal tissue. Though no existing photosensi-
tizer meets all of these criteria, agents which have been
used include: hematoporphyrin, photofrin, boronated por-
phyrin, talaporﬁn sodium, meta-tetrahydroxyphenylchlorin
(mTHPC), and metabolic precursors of protoporphyrin such
as 5-aminolevulinic acid [18]. As such, the search for
improved agents continues.
Light delivery: dosimetric concepts
Mechanistically, PDT proceeds through the activation of a
photosensitizer by light of a speciﬁc wavelength to produce
the putative reactive oxygen species, singlet oxygen. This is
the initial photochemical event that results in the destruc-
tion of photosensitizer bearing tissues [18]. Therefore one of
the primary requirements when treating tumors using PDT is
that a homogenous and dosimetrically sufﬁcient dose of light
is delivered to a tumor, which bears a therapeutic concen-
tration of the administered photosensitizer [21]. This results
in what has been referred to as the ‘‘photodynamic dose’’
and is deﬁned as the area under the curve of sensitizer level
plotted as a function of light dose [22]. In this way the efﬁ-
cacy of PDT as well as toxicity related to the therapy can be
directly linked to the dose of light delivered [21]. The gen-
eral range of wavelengths used for the broad applications of
photosensitizer excitation in PDT procedures has been from
approximately 405—900 nm. In this range there is a signiﬁ-
cant variance of depth of penetration into tissues. The use
of this range of wavelengths is dependent on two impor-
tant factors: (1) What is the depth of penetration one would
like to achieve and (2) what are the wavelengths of absorp-
tion of the particular photosensitizer being administered.
The photosensitizers may have more than one wavelength
at which sufﬁcient absorption will occur that would result
in a likewise sufﬁcient amount of singlet oxygen produced
(quantum efﬁciency). The shorter wavelengths of light will
have considerably shallower depths of penetration in most
human tissues. The use then, of PDT, requires the appropri-
ate matching of these factors.
One of the principal requirements for efﬁcacious treat-
ment of tumors in the brain is to achieve adequate light
illumination throughout the targeted tissue volume. This
would require various techniques to be employed deliver-
ing the total optical power for optimum penetration and
the corresponding diffusion of the spatial distribution of
that power with the size and shape of the illumination vol-
ume [23,24]. The light dose delivered and the method by
which it is delivered is crucial to the success of treatment
and the one major factor which can be controlled during
PDT. The aforementioned ‘‘photodynamic dose’’ describes
the amount of light necessary to achieve tumor eradica-
tion in a given application. This is different than the often
quoted attenuation length [25]. The attenuation length is
described as the distance into the tissue or media where
the applied light is reduced to approximately 37%. This
attenuation length is dependent on factors such as reﬂec-
tion, scattering, and absorption, and is analogous (using
natural logs) to the path length needed for an absorbance
unit of one in spectroscopy. Light attenuation can be mod-
eled by a ﬁrst-order decay type mechanism, and thus light
attenuation can be calculated at other depths than those
measured [25]. Further attenuation of the light occurs in
cases of divergent sources, such as in spherical and cylin-
drical emitters where the inverse square law comes into
play, so calculated attenuation would be further reduced
by these geometries. This attenuation length, however is
not necessarily the equivalent of ‘‘photodynamic dose’’.
Other factors also impact the photodynamic dose, such as
the concentration of oxygen radicals attacking the tumor
cells, the extinction coefﬁcient of the photosensitizer, the
concentration of the photosensitizer achieved in the cell,
the quantum yield for conversion of activated molecules
into radicals, and local oxygen availability [26]. For wave-
lengths in the 625—640 region one attenuation length is
described as approximately 3—5mm. However the currently
applied light dose, which is used in conventional PDT results
in a therapeutic photodynamic dose effective at approxi-
mately 0.8—1.0 cm in depth at 630 nm [26]. Light applied
will transmit through tissues at greater depths. The ulti-
mate effective therapeutic dose can be manipulated by
factors other than total light dose delivered, such as the
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wavelength used, geometry of light delivery, and localiza-
tion of illumination, such as spot irradiation or interstitial
delivery. Other concepts being considered are pulsed rather
than continuous light, and fractionated delivery through-
out the post-op period. By increasing the total number of
photons incident on the tissue one can effectively increase
the number of photons at depth. Table 1 shows a selective
review of light penetration values in a variety of tissues.
The values reported in Table 1 are highly variable, repre-
senting both the wide variety of experimental protocols,
and also indicative of large sample-to-sample variation.
Most reported values for this parameter are in the range of
1—4mm, with values as high as 1 cm[27] and 6.5mm [28].
By comparing the calculated attenuation at various depths,
it can be seen that most of the light energy is lost within
the ﬁrst 5mm, with only small amounts reaching the 1 cm
level. In most cases, essentially little or no light energy is
expected to reach beyond 1 cm.
The effective therapeutic effect, that of actual depth of
necrosis, is one that is more relevant clinically. Table 2 con-
tains a review of data on depth of necrosis, as demonstrated
by histological analysis of cells or tissue samples. Studies
include both animal models and clinical specimens. Ani-
mal models include both normal tissue and tumor. Although
necrosis of normal tissue can be seen, given large enough
doses of light and PS, selective tumor kill normally results
[28,33—35]. Depth of necrosis values reported in Table 2 are
also highly variable. Typical values range from 2 to 7mm,
with isolated values as high as 2 cm [28] and 15mm [36].
Given the high variability in tissue, tumor, and protocol
selections, this variability is not unexpected. As in the pen-
etration data, one can safely infer a measurable degree of
necrosis to a depth of about 5mm, with efﬁcacy to about
1 cm not unreasonable. This is also the depth given in the
ofﬁcial PDT website of the National Cancer Institute [37].
Light sources and light dispersion
Various delivery methods have been employed for emitting
light into the brain. Initially, argon-dye laser and xenon
arc light sources were commonly used. Diode lasers were
ofﬁcially introduced into the PDT ﬁeld around the year
2000 and have been the latest technological development
to gain approval for PDT. They have remained a main-
stay for PDT since that time. More recently, light emitting
diode (LED) arrays have been shown to be an effective
and a less costly means of light delivery [44]. Develop-
ments in LED technology have provided higher power and
narrower spectral characteristics making them a desirable
alternative to lasers. Ensuring adequate dispersion of light
to the area of desired treatment has also been dealt with
through various strategies using ﬁber optic devices. Standard
approved indications for PDT employ cylindrical diffusing
ﬁber tips. These are particularly well adapted to the treat-
ment of luminal disease such as encountered in pulmonary or
esophageal tumors. They are also suited to interstitial PDT
when implanted directly into the tumor mass. Interstitial
PDT for brain tumors involves the stereotactic placement of
ﬁbers directly into the brain tissue. Illumination for intra-
cavitary PDT can be achieved by placing the light emitting
source in the space created by tumor resection [31]. The
light source can be enclosed inside a balloon which is inﬂated
by ﬁlling the balloon with a diluted liquid photodistributor
such as intralipid, which evenly distributes light through-
out the balloon. The balloon facilitates a spherical geometry
coplanar to the resection cavity. A ﬁnal strategy is to con-
tinuously irrigate the resection cavity with photodistributor,
thereby tempering heat that may arise within the resection
cavity as well as reducing blood accumulation, which
would attenuate the light distribution during PDT treatment
[45].
Tumoral response to PDT
There is considerable interest in the basic science arena
to improve the tumoricidal effectiveness of PDT. Much of
the pertinent investigation has been focused on understand-
ing how nitric oxide (NO) signaling pathways in tumor cells
respond to the stress of PDT-induced ROS-mediated dam-
age. The nature and roles of these pathways in tumor cells
has yet to be fully elucidated. It is apparent that NO can
serve as either a pro- or anti-tumor mediator, depending on
a number of complex variables [46]. Nitric oxide has been
shown to play a cytoprotective and growth-stimulatory role
in a variety of cancers such as melanoma, gastric, breast,
colon, and head and neck carcinomas [47]. Researchers from
our institution have published in vitro data indicating that
breast cancer cell line exposed to 5-ALA based PDT therapy
had signiﬁcant upregulation of inducible nitric oxide syn-
thase (iNOS). Additionally, tumoricidal activity was shown
to be greatly enhanced through various methods of inhibi-
tion of the nitric oxide pathway [48,49]. Currently, no similar
experiments reporting a PDT-induced iNOS/NO upregulation
as a possible mechanism of cytoprotection in brain tumors
exists. There is evidence, however, that glioma stem cells
depend on upregulation of iNOS for growth and proliferation
[50]. Therefore, it seems likely that gliomas would utilize
the upregulation of NO production during times of stress,
which would have clear relevance to PDT in the treatment of
intracerebral gliomas. Several human trials using GW274150,
an iNOS inhibitor, have been performed, evaluating its role
as an anti-inﬂammatory agent in the setting of autoimmune
disorders and migraine headaches [51,52]. Trials to evaluate
the role of iNOS inhibitors in promoting PDT effectiveness
may demonstrate that selective inhibition of this pathway
serves to counteract the cytoprotective effects of iNOS.
There are several other areas of research that show
promise for improving the effectiveness of PDT. A recent
study showed that the drug geﬁtinib, an EGFR inhibitor
originally developed for use in breast and lung cancers,
can enhance the photodynamic effect in brain tumor cells.
The mechanism is due to geﬁtinib-mediated inhibition of
the ATP-binding cassette transporter ABCG2. Inhibiting this
transport mechanism prevented the efﬂux of photosensi-
tizer from brain tumor cells and led to a more effective
PDT effect [53]. Other strategies include the develop-
ment of nanoparticles linked to photosensitizers with a
goal of speciﬁcally targeting brain tumor. By targeting the
nanoparticle-photosensitizers to tumor, this would limit
the systemic drug exposure. This use of nanoparticles to
improve the detection of tumors is being investigated
[54].
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Table 1 Selected depth of penetration data.
Author Photosensitizer
(if used)
Dose
(mg/kg)
Wavelength (nm) Geometry Model Penetration
deptha (mm)
% light remaining at depth
0.5 cm 1 cm 2 cm
Dougherty [28] 600—700 Planar Excised rat
tumor
6.5b 46 21 4.6
Dougherty [25] 630 Planar In vivo
animal
tissues
1.7—4.4 5.3—32 0.3—10 <0.1—1.1
Honda [29] 632 Planar Mouse sub-
cutaneous
carcinoma
1.4 2.8 <0.1 <0.1
664 1.54 3.9 0.2 <0.1
690 1.69 5.2 0.3 <0.1
Mitra [27] 630 Planar Erythrocyte
phantom
∼10 61 37 14
Muller [30] Photofrin 2—2.5 630 Spherical Intraoperative
normal
brain
1.0—2.1 0.7—9.3 <0.1—0.9 <0.1
Intraoperative
normal
brain + tumor
0.8—4.9 0.2—36 <0.1—13 <0.1—1.7
Intraoperative
malignant
brain tumor
1.5—4.1 3.6—30 0.1—8.7 <0.1—0.8
Powers [31] 633 Planar Normal rat
brain
1.5 3.6 0.1 <0.1
HpD 10 633 Planar 1.0 0.7 <0.1 <0.1
Svaasand [32] 660 Planar Normal
cadaver
brain
1.2—1.7 1.6—5.3 <0.1—0.3 <0.1
aDeﬁned as depth at which 37% of incident light remains.
bCalculated from 4—5% light remaining at 2 cm depth.
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Table 2 Selected necrosis depth data.
Author Photosensitizer Dose
(mg/kg)
Wavelength
(nm)
Fluence
(J/cm2)
Geometry Model Necrosis depth (mm)
Dereski [38] Photofrin II 12.5 632 140 Planar In vivo normal
rat brain
3.5
Dougherty [28] HpD 5 600—700 120 Planar Cutaneous and
subcutaneous
human tumors
Up to 20
Ferreira [39] HPDs 2 630 200 Planar Normal rat liver 1.9—3
Chlorines 1 660 200 3.5—4.4
Foscan 0.3 660 30 3.4
Jacques [40] Generic 5 630 240 Planar Normal rat liver 7a
Kaye [33] HpD 20—40 630 200—400 Planar Rat C6 glioma 4—7
Konaka [41] HpD 5 630 43 Spherical Human breast
metastases
2—5
Madsen [42] ALA 630 50 Spherical In vitro glioma
spheroids
0.9—1.2b
Olzowy [34] ALA 100 635 200 Planar Rat C6 glioma 2.7
Perria [36] HpD 5 633 9 Planar Human brain
tumor
(postmortem
histology)
15
Potter [43] Photofrin II 2 630 200 Planar Breast tumor 3.5c
180 Spherical Colorectal
cancer
2.5c
400 J/cm Cylindrical Amelanotic
melanoma
3.5c
Tudge [35] HpD 1 630 800 Planar Rat C6 glioma 2.2
aNecrosis depth calculated for generic photosensitizer using published light penetration and minimum photosensitizer dose data.
bCalculated necrosis depth from measured minimum light ﬂuence for necrosis and published light penetration data.
cNecrosis depth calculated using published light penetration and minimum photosensitizer dose data.
Fluorescence guided resection
There is strong evidence to support that improved outcomes
are associated with more complete surgical resections in
patients with malignant brain tumors [55,56]. However,
technical complexity of thorough tumor resection coupled
with the risk of global harm from injury to eloquent brain
severely limits neurosurgeons from achieving an ‘‘optimal’’
resection. In high-grade gliomas, the challenge becomes
even greater, as tumor borders become less deﬁnable with
invasion of malignant cells into normal brain tissue. In
one study, complete resections occurred in less than half
of high-grade glioma resections [57]. In order to address
this disparity, a technique known as ﬂuorescence-guided
resection (FGR) was developed.
Intraoperatively, FGR can be used to improve tumor
identiﬁcation and allow for more complete resections. By
reducing the remaining tumor burden as much as possi-
ble, subsequent tumor cell killing techniques will have
that much greater chance to achieve their goals. Techni-
cally speaking, FGR shares similarities to PDT because it
employs a hematoporphyrin derivative as the active com-
pound, along with visualization by externally supplied light.
In this manner, it is reasonable to consider these techniques
together, one for visualization, and the other for tumor
cell eradication. Indeed, FGR, along with photodiagnosis,
is considered as a PDT-technology [62]. Most often, inves-
tigators have utilized 5-aminolevulinic acid (ALA, typical
dose 20mg/kg), which converts into the active ﬂuores-
cent molecule protoporphyrin IX (PpIX). By exciting PpIX
with blue light in the wavelength range 375—440 nm, red
light emits in the visible spectrum, which in turn is rec-
ognized by light detectors that are built into instruments
such as intraoperative microscopes. Through this technique,
observers can visualize the malignant tissue bound by these
ﬂuorescent markers [58]. Many groups are now including
these FGR techniques into their PDT protocols. It should
be noted that any trial using FGR would, of necessity, also
involve PDT to some degree, as singlet oxygen would be
generated from the porphyrin compounds used to visualize
tumor. Therefore, even in FGR-alone trials, overall results
are attributable to both tumor resection and photosensitizer
activation.
Review of clinical trials
Although there have been numerous clinical trials on the
use of PDT in the treatment of malignant brain tumors,
the majority of these are uncontrolled phase I/II studies
(Table 3). Only one Phase III clinical trial for PDT, one for FGR
alone, and one for PDT + FGR have been conducted to date.
Further complicating the assessment of PDT efﬁcacy is the
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Table 3 Selected PDT studies for brain tumors.
Author Approach No. of
Patients
GBM AA Other brain
tumor
Photosensitizer Dose Light density Median survival (months) Progression
free survival
Overall Primary Recurrent
Stupp [14] Phase III TMZ 573 Control 287 Control 12.1 5.0
TMZ 286 TMZ 14.6 6.9
Akimoto [77] case
series
i/o cavitary
spot
14 10 4 Talaporﬁn
sodium
40mg/m3 27 J/cm2 26 9 Primary-23
Recurrent-3
Muragaki [3] case
series
i/o cavitary
spot
22 13 3 6 Talaporﬁn
Sodium
40mg/m3 27 J/cm2 27.9 24.8 Overall-20
GBM-12
Stylli [73] case
series
i/o cavitary 136 78 58 Hematoporphyrin
derivative (HpD)
5mg/kg 70—240 J/cm2 GBM 14.3 13.5
Intralipid pool AA 76.5 66.6
Rosenthal [75]
Phase I
i/o cavitary 28 16 8 Boronated
porphyrin (BOPP)
0.25—8mg/kg 25—100 J/cm2 GBM 5 11
Intralipid pool AA 18
Schmidtl [44]
Phase I
i/o cavitary
balloon
20 5 3 12 Photofrin 0.75—2.0mg/kg 100 J/cm2 6
Stummer [78]
Phase III
FGR 243 Control 115 Control 16 5-ALA 20mg/kg Control 13.5 3.6
FGR 122 FGR 17 FGR 15.2 5.1
Beck [80] case
series
Interstitial 10 10 5-ALA 20mg/kg 15
Kostron [81] case
series
i/o cavitary
superﬁcial and
interstitial
58 50 HpD 2.5mg/kg 250 J/cm2 19 7
Kostron [82] Phase
II
i/o cavitary 52 Control 26 Foscan (mTHPC) 0.15mg/kg 20 J/cm2 3.5
Balloon or
diffusor
PDT 26 8.5
Eljamel [84] Phase
III
FGR
post-operative
cavitary
27 Control 14 5-ALA FGR
Photofrin PDT
20mg/kg
2mg/kg
100 J/cm2 Control 5.6 Control-4.8
PDT-8.6
Repetitive
balloon
PDT 13 PDT 12.2
Lyons [83] Phase II FGR
post-operative
cavitary
73 ST 25 5-ALA FGR
Photofrin PDT
20mg/kg
2mg/kg
100 J/cm2 ST 4.6
Repetitive
balloon
ST + PDT 13 ST + PDT 9.2
IORT ST + IORT 18 ST + IORT 11.2
ST + PDT + IORT
17
ST + PDT + IORT 18.2
Muller [62,71]
Phase III
Unknown 77 Control 34 Photofrin 2mg/kg 120 Control 8
PDT 43 PDT 11
Muller [45] case
series
i/o cavitary 96 49 24 26 Photofrin 2mg/kg 58± 17 GBM 7.6 6.7 —
Balloon and
ﬁber
Non-GBM 15.5 13.8 —
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heterogeneity of these studies’ methods, adjuvant therapy,
and tumor subtypes.
Many excellent PDT review articles have been published
over the years, and a number of them present summaries
of clinical trials. Good examples have come from the pens
of Stylli [2,4], Kostron [59], Eljamel [60—62], and Bechet
[1]. Typically, a table is presented, with text giving a very
brief summary. As these trials are generally very differ-
ent in design and execution, it is exceedingly difﬁcult to
come to an overall understanding of the state-of-the-art
and to appreciate the direction the ﬁeld is going in. As an
alternative to this traditional summary method, we propose
to organize the trials by research group or institution, in
order to explore the approach to the problem each group
is taking, and to detail their progress and direction for the
future. These approaches may involve choice and dose of
photosensitizer, choice and dose of light, method of light
application, and use of additional techniques such as PD
and FGR. Most recent results will be focused on, and groups
that appear to no longer be active in the ﬁeld will not be
discussed.
In these summaries, we will try to focus on GBMs in par-
ticular, with lower grade gliomas included where studied. As
GBMs have the worst prognosis, it seems reasonable to focus
most attention in that area. If PDT is to have a future in
regard to malignant brain tumors (MBT), it would seem that
this is where it needs to prove itself the most. Many stud-
ies, however, present a mixture of diagnosis and histologies,
and it is not always easy or even possible to separate out the
relevant results.
In like manner, newly diagnosed and recurrent tumors
may be stratiﬁed or mixed. Some studies focus on one or
the other. Whenever possible, these results will be looked
at separately. Recurrent GBMs in particular seem to have
very poor survival; improvements here would be the most
impressive.
There are a number of possible outcome measures, but
the most common appear to be median overall survival (OS)
and progression free survival (PFS). As OS reﬂects the effect
of other factors and therapies beyond merely PDT and FGR,
current thinking is that PFS is the preferred outcome mea-
sure; unfortunately it appears that, up to now, OS has been
the more widely reported measure. These outcomes will be
looked at in these summaries. Some trials may not report
these however, and we may be forced to use some other
measure of efﬁcacy.
A word needs to be said regarding comparators. An ideal
situation would of course be one with a control arm that is
included in a random controlled trial (RCT). This situation is
sadly rare, however. Most reports include no comparators,
other than a perhaps vague bow to ‘‘historical controls’’.
Some will cite literature surveys or meta-analyses. Better
yet, in case series studies, are closely matched local control
series, or even a control arm that was not assigned randomly.
In any case, a common problem is determining whether any
efﬁcacy has been demonstrated at all. In general, reported
‘‘normal’’ values for gliomas, especially for GBMs, seem to
vary in the same range as ‘‘treatment’’ values where PDT
has been used. Barring direct comparison to a judiciously
determined control arm, it is nearly impossible to make a
determination of efﬁcacy, absent a very large and striking
improvement in OS and PFS values.
A further issue is the case of an RCT that shows signiﬁcant
improvement over the control arm, but still falls short of
or is similar to common ‘‘normal’’ values. While efﬁcacy
has been shown in that study and with that protocol, will
this really translate to a beneﬁt in the world at large? Was
there something unique to the study group that invalidates
translating these results outside, or was this just the result
of the patient population, local conditions, etc.? We will not
really know until we reach the stage of large, multi-center,
Phase III trials.
Finally, we will attempt to compare these values with
current standard-of-care. As the PDT ﬁeld has been evolv-
ing since 1980, so too other treatment options have been
improving. For PDT to be a viable choice, it will need to
equal or exceed other options, or demonstrate an additional
beneﬁt when used in conjunction with the latest therapies.
Standard of care
In 2005, Stupp [14] reported on a pivotal trial for use of
temozolomide (TMZ) in conjunction with radiotherapy (RT)
and surgical resection in treatment of GBM. This was a
large, multi-center, Phase III trial comparing SR + RT against
SR + RT +TMZ. The control arm contained 286 subjects, while
the treatment arm contained 287. Median OS for the treat-
ment arm was 14.6 months, vs. 12.1 for the control. PFS for
the treatment arm was 6.9 months, vs. 5.0 for the control.
These differences were signiﬁcant. The use of concomitant
and adjuvant TMZ has now become standard-of-care for
newly-diagnosed primary GBM. As for recurrent GBM, there
are few FDA approved modalities including Gliadel wafers
(carmustine wafers), bevacizumab and NovoTTF-100A, also
called tumor treatment ﬁelds (TTFields). While each is novel
in its treatment approach, none have dramatically improved
the outcome at the time of recurrence. Giladel wafers pro-
vided a median survival advantage of 2 months compared
to placebo [63]. Bevacizumab improves PFS but has no sur-
vival advantage [64,65]. Most recently, NovoTTF therapy has
proven to be as effective as chemotherapy at the time of
recurrence [66] and may actually improve OS to 9.6 months
based on one retrospective study [67]. These values are now
the standard by which any PDT results should be compared.
Toronto
Muller and associates published a variety of cases series
through the 1990s involving various mixtures of gliomas,
light doses, and light application methods [66—73]. In gen-
eral, they used Photofrin in low to moderate light doses, and
intraoperative (i/o) cavitary balloon application with sup-
plementary interstitial application in some cases. Results
were modest, with OS values for newly-diagnosed GBM of
6—9 months, and recurrent GBM of 6—7 months. In 2006,
they published a larger, updated, case series with 112
patients [45]. The photosensitizer was ﬁxed at 2.0mg/kg of
Photofrin, but the light dose was varied, with an average of
58± 17 J/cm2. Light application was by i/o cavitary balloon
or bare ﬁber in Intralipid pool. Results were not improved
from the earlier series, with OS for newly-diagnosed GBM of
7.6 months, and recurrent GBM of 6.7 months.
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A Phase III trial with 150 newly-diagnosed and 120
recurrent gliomas was planned and listed in ClinicalTri-
als.gov (NCT00003788). It appears, however, that this trial
was closed short of enrollment goals. A 2006 conference
proceeding was reported [71], but no full report seems to
have been published. Some details can be obtained from a
review by Eljamel [62]. The photosensitizer was Photofrin at
2mg/kg, and the light dose was 120 J/cm2. Eljamel reports
the light used were 532 nm, but it is more likely that it
was 632 nm, consistent with previous trials and the rec-
ommended wavelength for use with Photofrin. The light
application was not stated, but it could be assumed to be
some form of i/o cavitary, based on earlier studies. The OS
for the treatment group was 11 months vs. 8 months for
the control. The difference was stated to be signiﬁcant,
but the life-curves crossed at 15 months. Although there
seems to be a signiﬁcant 38% improvement over the con-
trol group, these results are still unimpressive compared to
general experience with GBMs and standard-of-care. The
light dose may have been insufﬁcient, as many groups are
moving toward increased doses; in particular Kaye and Whe-
lan at 240 J/cm2.
Melbourne
Kaye started out, in a publication from 1987, with HpD PDT
in a Phase I/II trial and performed a light dose escalation
study up to 230 J/cm2 [72]. This protocol, with light doses
up to 240 J/cm2 was put into practice, and resulted in a
large case series [73] published in 2005 that resulted in OS
values of 14.3 months for newly-diagnosed, and 13.5 months
for recurrent GBMs. The higher light doses were associated
with better OS. The HpD used was manufactured in-house;
the dose of 5.0mg/kg would be equivalent to 2.5mg/kg of
the commercially available HpD Photofrin. Application was
by i/o ﬂat-cut laser ﬁber inserted in an Intralipid pool in the
resection cavity. The result for the newly-diagnosed GBMs
was higher than many of the typical non-PDT results of the
time (OS of 8.5—14.2 months in various studies), and is com-
parable to current standard-of-care.
Kaye has also investigated a new PS, boronated porphyrin
(BOPP). A 2003 report [74] presents the efﬁcacy results for
a 2001 safety study using this PS [75]. The approach was
the same as with HpD, but the PS dose was escalated from
0.25 to 8mg/kg, and the 630 nm light was escalated from
25 to 100 J/cm2. OS results for newly-diagnosed GBMs were
5 months, and for recurrent GBMs 11 months. These results
are for all doses pooled, so cannot be directly compared to
other studies.
Milwaukee
The Whelan group reported in 2004 a phase I toxicity study,
which enrolled 20 patients diagnosed with recurrent high-
grade gliomas [44]. Patients received PDT treatment using
a variety of light source and PS combinations. Photofrin
was delivered in 18 subjects, receiving doses (0.75, 1.2,
1.6, 2.0mg/kg) spanning an 18—24 h period; 10 of these
subjects received the maximum 2.0mg/kg, while eight
received lower than the maximum dose. Two patients
received benzoporphyrin derivative (BPD, 0.25mg/kg) in
lieu of Photofrin, whose absorption peaks are 630 nm and
680 nm, respectively. Photoillumination was achieved by
laser light, combined with either ﬁber-optic catheter or with
laser ﬁber balloon adapter (intracavitary PDT), or LED light
using a balloon adapter (LED-PDT) containing 144 LED chips.
Both light sources were calibrated and adjusted to produce
a total light dose of 100 J/cm2. Though ﬁber-optic laser-
induced photoillumination, and intracavitary PDT resulted in
two separate complications, PDT exposure in sensory cortex,
motor cortex, and visual cortex, especially by intracavitary
PDT, did not result in additionally deﬁcits. It appears that
broader dispersion of light intensity mitigated heat expo-
sure in tissue, so as to dampen power density achievable
by this modality. Patients who underwent LED-PDT did not
experience any signs of neurotoxicity or motor deﬁcit, even
when tumor extended into or arose adjacent to eloquent
brain. The advantages of LED-PDT cited at the time included
improved activation of photosensitizer deeper into brain
tissue relative to laser-based PDT, afforded by a broader
emission spectrum of LED (630—940 nm light) compared to
laser-light, as well as improved temperature monitoring
capabilities by the LED emitting instrument used. Finally,
since the major absorbance peak of BPD is much closer
to the major emission peak of LED, this combination of
photosensitizer and light-source seemed to have been the
best coupling, owing to more efﬁcient energy transfer and
decreased treatment time.
A Phase I clinical trial (NCT01682746) has been initiated
to determine the safety and dose response of PDT in chil-
dren. Using step-wise dose-escalation of Photofrin, we are
aiming to determine the maximally safe dose for pediatric
patients. At this time, three patients with infratentorial
tumors have been enrolled and treated, using a dose of
0.5mg/kg of Photofrin. Clinically, PDT has had no negative
effects on these patients.
Another area of investigation is a phase II adult trial that
is in development (NCT01966809). This trial will use the
higher light doses described by the Melbourne group [73].
At present, there has not been a North American trial using
PDT to this level of effectiveness. Initially, the study aims
to reproduce the survival improvements reported and deﬁne
the antitumor activity of Photofrin in a domestic (to the USA)
setting. Beyond the clinical treatment arm of this trial, the
plan is to further investigate the ﬁeld of detection and util-
ity of PDT as an adjuvant to other treatment paradigms,
through high-resolution imaging and pre-clinical studies.
Japan
Kaneko reported in 2008 a very large case series involving
250 subjects with 5-ALA FGR and 63 subjects undergoing HpD
PDT with a mixture of i/o cavitary and interstitial applica-
tion [76]. No survival data was presented. In 2012, Akimoto
reported a small case series of mixed gliomas, mostly grade
IV, treated with talaporﬁn sodium and 664 nm light [77].
Application was i/o cavitary with optically guided spot irra-
diation of the walls of the resection cavity. The OS for
newly-diagnosed gliomas was 26 months and the PFS was
23 months. For recurrent gliomas, OS was 9 months and PFS
was 3 months.
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Muragaki reported in 2013 a Phase II study using the same
approach. Twenty-two malignant gliomas were included, 13
of which were GBM [3]. An unstated number were recur-
rent. For all 22 gliomas, OS was 27.9 months and PFS was 20
months. For the 13 GBMs, OS was 24.8 months and PFS was
12 months.
These results for newly-diagnosed GBM are intriguing
and warrant further investigation, as they show substantial
improvements over other reports, and substantially higher
OS than current standard-of-care. Numbers were few, how-
ever, and MGMT methylation and other molecular marker
status was not reported, so the involvement of these pro-
gnostic markers in the results cannot be ascertained. This
protocol should be tested in the context of a Phase III RCT.
Munich
Stummer focused his attention in a 322-patient multi-center
Phase III RCT (2006) on FGR using 5-ALA as a means to
improve the completeness of surgical resection; PDT was
not included [78]. Primary endpoints were number of sub-
jects with residual tumor and 6-month progression-free
survival. Compared to controls with conventional surgery,
FGR gave more complete resections and better progression
free survival. OS was not improved signiﬁcantly (15.2 vs.
13.5 months), but a subsequent analysis of the same data
showed that complete resection was associated with sig-
niﬁcantly better OS in RTOG-RPA classes IV (17.7 vs. 12.9
months) and V (13.7 vs. 10.4 months) [79]. These values are
comparable to standard-of-care.
The assumption behind this approach is that better
resection, obtained by FGR, will eventually give better OS,
even if not seen in the current data when comparing FGR
and control arms. FGR gives more complete resections, and
complete resection is generally associated with better out-
comes. In this case, FGR did not give better OS, but did give
better six-month PFS. Stummer plans to add TMZ in future
trials. Meanwhile, they have begun exploring interstitial PDT
with 5-ALA (2007) and have determined that it is safe, and
obtained an OS of 15months in a series of 10 recurrent malig-
nant gliomas [80]. This value for recurrent tumors is similar
to standard-of-care for newly-diagnosed tumors.
Innsbruck
Kostron published a case series in 1994 using HpD at
2.5mg/kg and light at 250 J/cm2 applied i/o cavitary super-
ﬁcially to the tumor bed or interstitially [81]. OS for the
primary GBMS was 19 months, and 7 months for recurrent
GBMs. These results are a little higher than typical, and
higher than standard-of-care for newly-diagnosed GBMs.
A phase II trial with matched control case series was pub-
lished in 2006 [82]. This protocol used Foscan (mTHPC),
FGR and i/o PD at the tumor margin, and 652 nm light
at 20 J/cm2. Light was applied i/o cavitary using balloon
catheters or spherical or cylindrical diffusers. OS for the PDT
arm was 8.5 months, and 3.5 months for the control arm.
While the improvement over control is more than double, all
results are lower than typical and standard-of-care. It is not
clear that the use of Foscan FGR/PDT is any improvement
over HpD PDT alone.
Dundee
Eljamel has developed a rather different approach to the
technique. His protocol involves a combination of PD, FGR,
and post-operative PDT, and has been offered in Dundee
since 2001 [83]. Photofrin 2mg/kg is administered 48 h
prior, with 5-ALA 20mg/kg administered orally the day of
surgery. PD is used at time of resection to conﬁrm diagno-
sis, and white light resection is performed. This is followed
by ALA-FGR, with PPIX spectroscopy of the resected tumor
margin to conﬁrm completeness. A balloon catheter is then
emplaced, and allowed to remain for 5 days. Upon awak-
ening, PDT at 100 J/cm2 is administered, repeated every
24 h for a total of 5 treatments. Repetitive treatments are
administered to allow the PS to be replenished from sys-
temic stores after local bleaching during PDT. After 5 days,
the catheter is removed. RT and CHT may be included
after surgery [61]. Since 2005, intra-operative radiothe-
rapy (IORT) has also been offered in conjunction with PDT
[83].
This protocol is based on the following reasoning: case
series studies indicate usefulness of PDT. One-shot appli-
cations appear to not be effective, likely due to residual
tumor and insufﬁcient light. The Stummer FGR RCT showed
effectiveness at improving resection, but was insufﬁcient at
improving OS as invading tumor cells are still present micro-
scopically, regardless of resection completeness. Therefore,
a combination of PD, FGR, and PPIX spectroscopy is used to
maximize tumor resection, while PDT and IORT is used to kill
all residual tumor cells. All steps are necessary, as PDT with-
out complete resection leaves tumor areas that can regrow,
while complete resection without PDT still leaves individual
invading cells to regenerate tumor.
In 2008, a single-center Phase III RCT using the above
protocol (no IORT) was published for primary GBM [84]. OS
for the control group was 5.6 months, while the PDT group
was 12.2 months. PFS for the control was 4.8 months, vs. 8.6
months for the PDT group. Although a signiﬁcant survival
and progression improvement was shown, it is not known
if this is due to FGR or PDT separately, or together. These
results are lower than typical values and are attributed to
a much greater proportion of poor prognosis factors in the
study population.
A larger multi-center Phase III trial was called for, but in
a 2010 review Eljamel [62] claims that the case is proven,
and to require further trials would be unethically denying
treatment to the placebo group.
In 2011 Lyons published a 73-patient case series using the
above PDT protocol for GBM with the addition of IORT [83].
No information was given whether these cases were newly
diagnosed or recurrent. There were four groups: standard
therapy (ST), ST + PDT, ST + IORT, and ST + PDT + IORT. OS
for the combined PDT groups was 14.5 months, a signiﬁ-
cant improvement over ST alone, which was 4.6 months.
OS for ST + PDT + IORT at 18.2 months was a non-signiﬁcant
improvement over ST + PDT at 9.2 months. PDT provided a
statistically signiﬁcant survival advantage, while the addi-
tion of IORT looks promising, but was not signiﬁcant.
Again, survival values are not impressive when compared
to standard-of-care, while the control group in particular
fared poorly than is typical.
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Infratentorial tumors
Though most studies of PDT have been restricted to treating
neoplasms that arise above the tentorium cerebelli (supra-
tentorial) away from functional cortex and the brain stem,
PDT can be used to treat infratentorial malignancies. Due to
the proximity of posterior fossa tumors to eloquent brain-
stem and other vital structures, most therapies pose threats
immediately, or from long-term complication. Similarly, PDT
may incite brainstem toxicity, but some evidence exists to
defend its use in treating these tumors.
In pre-clinical studies using a canine animal model for
infratentorial glioma, tissue from brain stem and other pos-
terior fossa contents were analyzed to characterize the risks
and adverse effects of PDT in this region. Effects from both
high and low doses of photosensitizing agent were com-
pared [85]. Events attributable to experimental intervention
included neurotoxicity, which was deﬁned as a decline
in neurological function occurring within 1 week of PDT
and persistent to 4 weeks post-PDT. Additionally, although
high doses of Photofrin-II (2—4mg/kg) incited severe neu-
rotoxicity in these animals, lowered doses of Photofrin-II
(0.75mg/kg) resulted in signiﬁcant tumor cell death with
only ‘‘mild’’ neurotoxicity, according to Common Terminol-
ogy Criteria for Adverse Events (CTCAE) [86].
Clinical application of PDT for treatment of infratentorial
glioma includes the work by Laws et al. [87], which demon-
strated no signiﬁcant toxicity in 4 patients with posterior
fossa neoplasm (2 medulloblastomas, 2 ependymomas). In
another PDT trial conducted at our institution, IV Photofrin
and 100 J/cm2 of light were administered to 20 patients with
recurrent brain tumors, which included four patients with
infratentorial tumors either involving or immediately adja-
cent to brain stem [44]. We reported one adverse event in
a single patient, which was attributed to high power den-
sity of a small spherical dispersion tip, and our results from
this trial support the clinical application of PDT to treat
malignant tumors located in or near the brain stem.
Discussion
There are four basic approaches used by the various research
groups involved in the clinical trials reported here, with
overlap between some. The ﬁrst, seen in Toronto, Mel-
bourne, and Milwaukee, involves (usually) a single cavitary
balloon or ﬁber/Intralipid PDT application using HpD, or the
more potent commercial version Photofrin. When sufﬁcient
PS and light doses are given, results are encouraging. The
point has not been proven, however, with an adequate Phase
III trial.
The second approach seen in Japan uses a newer PS,
talaporﬁn sodium, and optically-guided cavitary spot light
application. Results are the most promising of all so far, but
only small case series are reported.
In a third approach taken in Innsbruck in a Phase II series
with matched controls, FOSCAN was used both for FGR and
i/o cavitary PDT. While results were improved over controls,
they are poor compared to other groups.
Finally, Eljamel has combined Stummer’s work on ALA-
FGR with repetitive post-operative cavitary HpD PDT in a
small Phase III trial. Again, while improvement over controls
is seen, results compared to historical norms and standard-
of-care is poor. An addition of IORT, while conﬁrming the PDT
results, does not give further improvement. Larger multi-
center Phase III trials may sort out whether the poor results
are purely a local phenomenon.
The use of photodynamic therapy in the treatment of
brain tumors has produced exciting results in clinical trials
over the past decade and yet it has failed to be established
as a common adjuvant therapy with the exception of a few
specialized international centers. The purpose of this arti-
cle was to review the relevant data about this treatment and
provide some insight into the future directions in the search
to improve the outcomes for a patient population that has
long been faced with a dismal prognosis. Future prospec-
tive clinical trials involving PDT are needed to determine its
efﬁcacy with current therapeutic regimens.
Moving forward, experimental designs of PDT studies may
be better served by expounding upon the characteristics of
the tumor populations that have beneﬁted from this ther-
apy. Since the clinical experience reported by Stylli et al.
[73], results from various prospective trials such as Stupp’s
Phase III trial using adjunctive radiation and temozolomide
have defended the use of chemoradiation for treating pri-
mary GBM [88]. While the results from the Australian-led
PDT trial rival the survival outcomes achieved by today’s
standard of care in adults, the post-PDT data unintentionally
overlooks factors such as differential expression patterns
within tumor cell populations (e.g. MGMT-methylation sta-
tus, IDH-1 status). These are considered valid predictors of
survival following administration of today’s standard of care
[89]. While it is unclear if PDTs efﬁcacy will be limited by
aberrant function that protects tumor cells against chemora-
diotherapy, it is certain that further investigation of PDT’s
penetration capacities and long-term survival will be needed
to determine which properties hinder this intervention. Nev-
ertheless, a clear advantage of PDT at the moment would
appear to be its safety proﬁle, evidenced by a low inci-
dence of adverse effects compared to novel agents, such
as those targeting VEGF, like Bevascizumab (Avastin). In
addition to Avastin’s inability to improve overall survival
for patients with recurrent GBM, the propensity of this
novel inhibitory agent of VEGF to induce systemic delete-
rious effects also threatens the predilection for using this
adjunct [89]. Having already demonstrated effectiveness at
>230 J/cm2 and improvement from the survival trends, espe-
cially for recurrent anaplastic astrocytomas, not to mention
safe practice in infratentorially-based tumors, PDT may bet-
ter serve vulnerable populations compared to other agents.
Its use as an adjunct to gross-tumor resection and/or chemo-
radiotherapy treatment strategies seems to be a viable
option in these situations and ongoing trials will help elabo-
rate to what the extent it will improve the ﬁeld of malignant
glioma therapy.
Conclusion
Future questions to explore include whether PDT can be
employed to treat less malignant tumors whose location
makes resection impossible — ‘‘malignant by location.’’
Also, the ﬁeld of ﬂuorescence-guided resection is creat-
ing the opportunity for combinations with PDT that may
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prove synergistic in the treatment of brain tumors. Contin-
ued research in PDT will determine whether the advances
shown in cancer research will mitigate morbidity and mor-
tality from treating intracranial malignancies, but certainly
the potential for this modality to revolutionize the treat-
ment of brain tumors remains. The various uses for PDT in
clinical practice should be thoughtfully pursued.
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